Neuropsychiatric Events Most Frequently Occur at SLE Diagnosis
Researchers examined the association between neuropsychiatric events and health-related quality of life in a cohort of patients with systemic lupus erythematosus.
Systemic Lupus Erythematosus
SYSTEMIC LUPUS ERYTHEMATOSUS
-
-
Visual Analog Scale Assessments Can Reliably Assess Disease Severity in SLE
Researchers compared the performance of 2 visual analog scale-based assessments, SSPGA and LFA-REAL, with outcome measures from other lupus trials. -
Renal Arteriosclerosis Develops Prematurely in Lupus Nephritis
A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls. -
High Genetic Risk Score Associated With Organ Damage, Renal Dysfunction, and All-Cause Mortality in SLE
The study evaluated the association between high genetic disease risk and disease severity in patients with systemic lupus erythematosus. -
Peripheral Nervous System Disease Has Significant Negative Effect on Quality of Life in SLE
Peripheral nervous system (PNS) disease is a component of systemic lupus erythematosus (SLE) disease activity and has a significant negative impact on health-related quality of life. -
Antimalarial Drugs May Reduce Polyautoimmunity in Systemic Lupus Erythematosus
Researchers evaluated the frequency of polyautoimmunity and its associated factors in a large retrospective cohort of patients with systemic lupus erythematosus. -
Belimumab Associated With Meaningful Improvement in Lupus Nephritis Trial
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients. -
Anifrolumab Improves Response at 52 Weeks in Lupus
For patients with systemic lupus erythematosus (SLE), anifrolumab is associated with improved response at 52 weeks versus placebo. -
Itolizumab Receives Fast Track Status for Lupus Nephritis
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis. -
No Significant Effect of Belimumab on Levels of Certain Anticardiolipin Antibodies in SLE
Researchers assessed the effect of belimumab vs placebo on antiphospholipid antibodies from 2 large randomized controlled trials, BLISS-76 and BLISS-52.
LATEST NEWS
Voclosporin Superior to Standard of Care in Lupus Nephritis Trial
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
Newly Diagnosed SLE Associated With Increased Risk for Hip Fractures
Researchers assessed the independent risk of hip fractures in patients with newly diagnosed systemic lupus erythematosus compared with the general population.
Atrial Fibrillation Hospitalization Rate Twice as High in Medicaid Recipients With SLE
Researchers investigated and compared the rates, risks, and risk factors for atrial fibrillation among Medicaid recipients with systemic lupus erythematosus (SLE) and age- and sex-matched Medicaid recipients without SLE.
Anifrolumab Superior to Placebo in Moderate to Severe Systemic Lupus Erythematosus
Although the first phase 3 trial of anifrolumab did not meet its primary end point, other study end points that were met suggested a clinical benefit for the monoclonal antibody in systemic lupus erythematosus.
Glucocorticoid Use Associated With Increased Risk for Cardiovascular Disease in SLE
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
Diagnoses of RA, SLE Linked to Increased Opioid Overdose Hospitalization Risk
Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.
High Doses of Hydroxychloroquine May Protect Against Thrombosis in SLE
Researchers examined the association of blood levels of hydroxychloroquine with thrombotic events in a longitudinal systemic lupus erythematous cohort.
Specific Factors Identify Cancer Risk in Systemic Lupus Erythematosus
Researchers studied cancer risk in patients with systemic lupus erythematosus and identified specific risk factors.
Item-Level Domain Analysis May Interpret Quality of Life Responses in SLE
Researchers explored the effect of disease activity on specific health-related quality of life over time in patients with systemic lupus erythematosus, using the item response theory longitudinal model.
Disease Flares Common After Discontinuing Immunosuppressants in Systemic Lupus Erythematosus
Researchers assessed the flare rate and predictors after immunosuppressant withdrawal in systemic lupus erythematosus remission.
Want to read more?
Please login or register first to view this content.
Next post in Systemic Lupus Erythematosus
